These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35001643)

  • 21. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson's: a study protocol.
    Sigurdsson HP; Hunter H; Alcock L; Wilson R; Pienaar I; Want E; Baker MR; Taylor JP; Rochester L; Yarnall AJ
    BMC Neurol; 2023 Feb; 23(1):58. PubMed ID: 36737716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial.
    Wilkinson D; Ade KK; Rogers LL; Attix DK; Kuchibhatla M; Slade MD; Smith LL; Poynter KP; Laskowitz DT; Freeman MC; Hoffer ME; Saper JR; Scott DL; Sakel M; Calhoun AH; Black RD
    Headache; 2017 Jul; 57(7):1065-1087. PubMed ID: 28656612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
    Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
    Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).
    Starling AJ; Tepper SJ; Marmura MJ; Shamim EA; Robbins MS; Hindiyeh N; Charles AC; Goadsby PJ; Lipton RB; Silberstein SD; Gelfand AA; Chiacchierini RP; Dodick DW
    Cephalalgia; 2018 May; 38(6):1038-1048. PubMed ID: 29504483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.
    Kinfe TM; Pintea B; Muhammad S; Zaremba S; Roeske S; Simon BJ; Vatter H
    J Headache Pain; 2015; 16():101. PubMed ID: 26631234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
    Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
    Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
    Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
    Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial.
    Schoenen J; Vandersmissen B; Jeangette S; Herroelen L; Vandenheede M; Gérard P; Magis D
    Neurology; 2013 Feb; 80(8):697-704. PubMed ID: 23390177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased migraine-free intervals with multifocal repetitive transcranial magnetic stimulation.
    Leahu P; Bange M; Ciolac D; Scheiter S; Matei A; Gonzalez-Escamilla G; Chirumamilla VC; Groppa SA; Muthuraman M; Groppa S
    Brain Stimul; 2021; 14(6):1544-1552. PubMed ID: 34673259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study.
    Grazzi L; Egeo G; Liebler E; Padovan AM; Barbanti P
    Neurol Sci; 2017 May; 38(Suppl 1):197-199. PubMed ID: 28527086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
    Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
    Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial.
    Cao K; Han F; Lin A; Yang W; Zhao J; Zhang H; Ding Y; Xie W; Xu Y; Yu T; Wang X; Yang X; Zhou J; Hou Q; Yu L; Gao Y
    BMC Complement Altern Med; 2016 Sep; 16(1):356. PubMed ID: 27618916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
    Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
    JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.